Claims for Patent: 10,092,525

Summary for Patent: 10,092,525

Title:	Use of cannabinoids in the treatment of epilepsy
Abstract:	The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Inventor(s):	Guy; Geoffrey (London, GB), Wright; Stephen (London, GB), Mead; Alice (Cambridge, GB), Devinsky; Orrin (New York, NY)
Assignee:	GW Pharma Limited (Vision Park, Histon, Cambridge, GB)
Application Number:	15/449,402
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,092,525
Patent Claims:	1. A method of reducing drop seizure frequency in a patient with Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) .DELTA.9-tetrahydrocannabinol (THC), and wherein the dose of the CBD is about 20 mg/kg/day. 2. The method of claim 1, wherein the CBD comprises .DELTA.9-tetrahydrocannabinol (THC). 3. The method of claim 1, wherein the CBD is administered in combination with one or more concomitant anti-epileptic drugs (AED) to the subject in need thereof at a recommended therapeutic dose of the AED. 4. The method of claim 3, wherein the one or more AED is selected from the group consisting of: clobazam; clonazepam, levetiracetam; topiramate; stiripentol; phenobarbital; lacsamide; valproic acid; zonisamide; perampanel; and fosphenytoin. 5. A method of treating drop seizures in a patient with Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the purity of the CBD is at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) .DELTA.9-tetrahydrocannabinol (THC), and where the dose of the CBD is about 20 mg/kg/day. 6. The method of claim 5, wherein the CBD comprises .DELTA.9-tetrahydrocannabinol (THC). 7. The method of claim 5, wherein the CBD is administered in combination with one or more concomitant anti-epileptic drugs (AED) to the subject in need thereof at a recommended therapeutic dose of the AED. 8. The method of claim 7, wherein the one or more AED is selected from the group consisting of: clobazam; clonazepam, levetiracetam; topiramate; stiripentol; phenobarbital; lacsamide; valproic acid; zonisamide; perampanel; and fosphenytoin.